Augmedix, a company that say it turns natural clinician-patient conversation into medical documentation, announced on Wednesday, that Joe Marks, executive director of the Center for Machine Learning & Health at Carnegie Mellon University has been named as the company's new director.
Marks brings to the company extensive experience across such disciplines as artificial intelligence and human-in-the-loop automation. He has run the research labs at both Mitsubishi Electric and The Walt Disney Company. He has worked on DARPA-sponsored research projects for the US government, co-founded two start-ups, and has served as an advisor and consultant to the American Medical Association, all in addition to his current work at Carnegie Mellon. At Augmedix, Marks' official title will be independent director.
Manny Krakaris, chief executive officer at Augmedix, said, 'Augmedix is aggressively pursuing automation innovation in medical note documentation, data aggregation, and analysis. Joe Marks has an established record of pushing technical boundaries of artificial intelligence and machine learning, particularly within health care. We're delighted to have someone of Joe's stature join our team and apply his unique expertise to enhance our efforts in this area.'
Dexcom highlights new diabetes outcomes and product roadmap at ATTD 2026
Curatis and Neupharma partner to develop corticorelin for peritumoral brain edema in Japan
Samsung Biologics collaborates with Lilly for new Gateway Labs site in Korea
Citius Oncology reports positive topline results from Phase 1 clinical trial of LYMPHIR combination
GenomOncology partners with WeTrials to support CNS cancer clinical trials
Target ALS awards two-year research grant to AcuraStem for advancing therapeutics targeting SYF2
Ascletis reports Phase II weight‑loss results for ASC30 depot formulation
NS Pharma and NCNP report 4.5-year brogidirsen data for DMD treatment
Biofrontera reports Phase 2b data for Ameluz photodynamic therapy in acne vulgaris treatment
Koselugo approved in Canada for adults with NF1 and inoperable plexiform neurofibromas
Bristol Myers Squibb reports positive Phase 3 results for oral mezigdomide in multiple myeloma
Pfizer reports positive Phase 2 results for trispecific antibody in atopic dermatitis
Agilent to acquire Biocare Medical for USD950m to expand pathology portfolio